Sector News

BioMarin apppoints Robert J. Hombach, Former Baxalta CFO and COO, to Board

October 4, 2017
Life sciences

BioMarin Pharmaceutical Inc., a global leader in providing therapies for rare genetic diseases, today announced the appointment of former Baxalta Chief Financial Officer and Chief Operations Officer, Robert J. Hombach, to its Board of Directors.

“We are thrilled to have Bob join BioMarin’s Board of Directors. He brings additional expertise in financial and operational management in the biopharmaceutical industry to an already outstanding board,” said Jean-Jacques Bienaimé, Chairman and Chief Executive Officer at BioMarin. “I am confident he will make meaningful contributions to support BioMarin’s growth as we continue to develop pioneering therapies for patients with rare genetic diseases.”

“I am honored to serve on the board of a company with a 20-year history of developing therapies that make a big difference for small patient populations,” said Robert J. Hombach. “I am looking forward to working with BioMarin as it continues to build its current business, while advancing a robust pipeline during a time of exceptional growth.”

Source: BioMarin

comments closed

Related News

November 26, 2023

ViCentra links insulin pump with Dexcom, Diabeloop tech to launch closed-loop diabetes system in Europe

Life sciences

Hybrid closed-loop systems rely on an algorithm to first analyze real-time blood sugar readings from a continuous glucose monitor, then use the results to adjust an insulin pump’s output as needed throughout the day. In this case, the algorithm was developed by Diabeloop, the CGM is a Dexcom G6 sensor, and the insulin pump comes from ViCentra.

November 26, 2023

Boehringer builds out cancer capabilities with $500M deal for bacteria-focused Swiss biotech

Life sciences

Boehringer Ingelheim has acquired bacterial cancer therapy company T3 Pharmaceuticals in a deal that could be worth up to 450 million Swiss francs ($508 million). The addition of Allschwil, Switzerland-based T3 will “significantly expand” the German drugmaker’s immuno-oncology pipeline and aligns with some of the company’s existing R&D programs.

November 26, 2023

EuroAPI completes acquisition of BianoGMP

Life sciences

EuroAPI has completed the acquisition of BianoGMP, a contract development and manufacturing organization (CDMO) specializing in oligonucleotides. The acquisition, announced in August, further differentiates its value proposition to support a broader client base across the whole oligonucleotide development continuum, from research to commercialization, EuroAPI said.

How can we help you?

We're easy to reach